Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | anti dorsalizing morphogenetic protein 1a | 0.0061 | 0.4322 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0039 | 0.1791 | 0.1791 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0039 | 0.1791 | 0.4144 |
Leishmania major | hypothetical protein, conserved | 0.0039 | 0.1791 | 0.5 |
Brugia malayi | Kringle domain containing protein | 0.0039 | 0.1791 | 0.1791 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.4217 | 0.4217 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.4217 | 0.4217 |
Brugia malayi | Transforming growth factor beta like domain containing protein | 0.0061 | 0.4322 | 0.4322 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0039 | 0.1791 | 0.4144 |
Loa Loa (eye worm) | bone morphogenic protein 6 | 0.0061 | 0.4322 | 0.4322 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0039 | 0.1791 | 0.5 |
Onchocerca volvulus | 0.0039 | 0.1791 | 1 | |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0039 | 0.1791 | 0.5 |
Echinococcus multilocularis | anti dorsalizing morphogenetic protein 1a | 0.0061 | 0.4322 | 1 |
Giardia lamblia | Hypothetical protein | 0.006 | 0.4217 | 0.5 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0039 | 0.1791 | 0.1791 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0039 | 0.1791 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0039 | 0.1791 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.1791 | 0.1791 |
Brugia malayi | Fibroblast growth factor family protein | 0.006 | 0.4217 | 0.4217 |
Brugia malayi | Fibroblast growth factor family protein | 0.006 | 0.4217 | 0.4217 |
Toxoplasma gondii | kringle domain-containing protein | 0.0039 | 0.1791 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0111 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.